{
  "conditions_to_closing": {
    "mutual_conditions_list": {
      "answer": [
        "The Required Company Stockholder Vote shall have been obtained.",
        "No injunction or similar order by any Governmental Authority that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect.",
        "No Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority that prohibits or makes illegal the Merger or the Carve-Out.",
        "Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out shall have expired or been earlier terminated.",
        "All other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained.",
        "All Requisite Regulatory Approvals shall be in full force and effect."
      ],
      "clause_text": "The obligations of the Parties to consummate the Merger are subject to the satisfaction, at or prior to the Closing, of each of the following conditions, to the extent applicable: (a) Stockholder Approval. The Required Company Stockholder Vote shall have been obtained. (b) No Legal Restraints. No (i) injunction or similar order by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect or (ii) Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that, in any case, prohibits or makes illegal the Merger or the Carve-Out (any such order, injunction, or Law in the foregoing clause (i) or (ii), a \"Legal Restraint\"). (c) Regulatory Approvals. (i) Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated, (ii) all other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained, as the case may be (all actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods, including under the HSR Act, of such jurisdictions, being the \"Requisite Regulatory Approvals\"), and (iii) all Requisite Regulatory Approvals shall be in full force and effect.",
      "reference_section": "Section 7.01"
    },
    "parent_closing_conditions": {
      "answer": [
        "The representations and warranties of the Company in specified sections must be true and correct as of the Closing Date, with certain exceptions for de minimis inaccuracies and materiality.",
        "The Company must have performed all obligations required under the Agreement in all material respects at or prior to the Effective Time.",
        "The Company must deliver a certificate, signed by a senior officer, certifying that certain conditions have been satisfied.",
        "No events or circumstances resulting in a Material Adverse Effect should have occurred since the date of the Agreement.",
        "Certain conditions related to Legal Restraints and Burdensome Conditions must be satisfied without imposing such conditions."
      ],
      "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); (ii) Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24 and Section 3.27 shall be true and correct in all material respects as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); and (iii) the other representations and warranties of the Company set forth in Article III (disregarding all materiality and Material Adverse Effect qualifications contained therein) shall be true and correct as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date), except with respect to this clause (iii), where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect. (b) The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Effective Time. (c) The Company shall have delivered to Parent a certificate, dated as of the Closing Date, and signed by its Chief Executive Officer or another senior officer, certifying to the effect that the conditions set forth in Section 7.03(a), Section 7.03(b) and Section 7.03(d) have been satisfied. (d) Since the date of this Agreement, there shall have occurred no events or circumstances that individually or in the aggregate have resulted in a Material Adverse Effect. (e) The condition set forth in Section 7.01(b) (if the Legal Restraint relates to any of the matters referenced in Section 7.01(c)) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing). (f) The condition set forth in Section 7.01(c) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
      "reference_section": "Section 7.03"
    },
    "company_closing_conditions": {
      "answer": [
        "The representations and warranties of the Company set forth in Section 3.03 and Section 3.08(a) must be true and correct as of the Closing Date.",
        "The representations and warranties in Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24, and Section 3.27 must be true and correct in all material respects as of the Closing Date.",
        "Other representations and warranties of the Company in Article III must be true and correct, except where failure would not have a Material Adverse Effect.",
        "The Company must have performed all obligations required under the Agreement in all material respects.",
        "The Company must deliver a certificate signed by its CEO or another senior officer certifying satisfaction of certain conditions.",
        "No events or circumstances resulting in a Material Adverse Effect must have occurred since the date of the Agreement.",
        "The condition in Section 7.01(b) must be satisfied without a Burdensome Condition.",
        "The condition in Section 7.01(c) must be satisfied without a Burdensome Condition."
      ],
      "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); (ii) Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24 and Section 3.27 shall be true and correct in all material respects as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); and (iii) the other representations and warranties of the Company set forth in Article III (disregarding all materiality and Material Adverse Effect qualifications contained therein) shall be true and correct as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date), except with respect to this clause (iii), where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect. (b) The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Effective Time. (c) The Company shall have delivered to Parent a certificate, dated as of the Closing Date, and signed by its Chief Executive Officer or another senior officer, certifying to the effect that the conditions set forth in Section 7.03(a), Section 7.03(b) and Section 7.03(d) have been satisfied. (d) Since the date of this Agreement, there shall have occurred no events or circumstances that individually or in the aggregate have resulted in a Material Adverse Effect. (e) The condition set forth in Section 7.01(b) (if the Legal Restraint relates to any of the matters referenced in Section 7.01(c)) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing). (f) The condition set forth in Section 7.01(c) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
      "reference_section": "Section 7.03"
    },
    "target_shareholder_approval_required": {
      "answer": true,
      "clause_text": "The Required Company Stockholder Vote shall have been obtained.",
      "reference_section": "Section 7.01 (a)"
    },
    "target_shareholder_approval_threshold": {
      "answer": "majority of the shares of Company Common Stock outstanding",
      "clause_text": "The affirmative vote of the holders of a majority of the shares of Company Common Stock outstanding on the record date for the Company Stockholders' Meeting in favor of adopting this Agreement (the 'Required Company Stockholder Vote') is the only vote of the holders of any class or series of the Company's capital stock, or any holder of any other security of the Company, necessary to adopt this Agreement and approve the Merger.",
      "reference_section": "Section 3.06"
    },
    "parent_shareholder_approval_required": {
      "answer": false,
      "clause_text": "No vote of Parent's stockholders is necessary to approve Parent's execution of this Agreement or the consummation of the Transactions.",
      "reference_section": "Section 4.04"
    },
    "parent_shareholder_approval_threshold": {
      "answer": "Not found",
      "clause_text": "",
      "reference_section": ""
    },
    "hsr_clearance_required": {
      "answer": true,
      "clause_text": "Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated.",
      "reference_section": "Section 7.01 (c)"
    },
    "other_customary_conditions": {
      "answer": [
        "Stockholder Approval",
        "No Legal Restraints",
        "Regulatory Approvals"
      ],
      "clause_text": "The obligations of the Parties to consummate the Merger are subject to the satisfaction, at or prior to the Closing, of each of the following conditions, to the extent applicable: (a) Stockholder Approval. The Required Company Stockholder Vote shall have been obtained. (b) No Legal Restraints. No (i) injunction or similar order by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect or (ii) Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that, in any case, prohibits or makes illegal the Merger or the Carve-Out (any such order, injunction, or Law in the foregoing clause (i) or (ii), a \"Legal Restraint\"). (c) Regulatory Approvals. (i) Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated, (ii) all other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained, as the case may be (all actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods, including under the HSR Act, of such jurisdictions, being the \"Requisite Regulatory Approvals\"), and (iii) all Requisite Regulatory Approvals shall be in full force and effect.",
      "reference_section": "Section 7.01"
    },
    "financial_conditions_minimum_cash_threshold": {
      "answer": "Not found",
      "clause_text": "",
      "reference_section": ""
    },
    "financial_conditions_maximum_net_debt": {
      "answer": "Not found",
      "clause_text": "",
      "reference_section": ""
    },
    "financial_conditions_minimum_any_condition": {
      "answer": "Not found",
      "clause_text": "",
      "reference_section": ""
    },
    "tax_conditions_tax_opinion_required": {
      "answer": "Not found",
      "clause_text": "",
      "reference_section": ""
    },
    "required_regulatory_clearances": {
      "answer": "HSR, CMA",
      "clause_text": "The obligations of the Parties to consummate the Merger are subject to the satisfaction, at or prior to the Closing, of each of the following conditions, to the extent applicable: (c) Regulatory Approvals. (i) Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated, (ii) all other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained, as the case may be (all actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods, including under the HSR Act, of such jurisdictions, being the \"Requisite Regulatory Approvals\"), and (iii) all Requisite Regulatory Approvals shall be in full force and effect.",
      "reference_section": "Section 7.01"
    }
  },
  "material_adverse_effect": {
    "mae_carveout": {
      "mae_carveout_general_economic_conditions_included": {
        "answer": true,
        "clause_text": "any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_general_economic_conditions_explanation": {
        "answer": "Adverse effects resulting from general economic conditions are excluded from the definition of Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: ... (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_industry_conditions_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_industry_conditions_explanation": {
        "answer": "any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates",
        "clause_text": "any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_stock_price_changes_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (i) any change in the market price or trading volume of the Company Common Stock...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_stock_price_changes_explanation": {
        "answer": "any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_credit_rating_changes_included": {
        "answer": true,
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_credit_rating_changes_explanation": {
        "answer": "Changes in credit ratings, analyst outlooks, or recommendations are excluded from the definition of Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_legal_or_regulatory_changes_included": {
        "answer": true,
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_legal_or_regulatory_changes_explanation": {
        "answer": "any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof",
        "clause_text": "any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_force_majeure_events_included": {
        "answer": true,
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event ...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_force_majeure_events_explanation": {
        "answer": "Acts of God, natural disasters, and weather-related events are excluded from the definition of Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_political_events_or_war_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (v) any domestic, foreign or global political, regulatory, or social condition... any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof)...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_political_events_or_war_explanation": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "mae_carveout_pandemic_health_events_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (v) any domestic, foreign or global political, regulatory, or social condition... pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure)...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_pandemic_health_events_explanation": {
        "answer": "Pandemics, epidemics, or public health emergencies, including COVID-19, are excluded from the definition of a Material Adverse Effect.",
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_agreement_compliance_effects_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_agreement_compliance_effects_explanation": {
        "answer": "The effects resulting from the negotiation, execution, or announcement of the merger agreement are excluded from the MAE definition.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_parent_actions_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (xiii) any action taken by Parent or any of its Affiliates;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_parent_actions_explanation": {
        "answer": "Adverse effects resulting from actions taken by the Company at the direction, request, or with the consent of the Parent or its Affiliates are excluded from the definition of Material Adverse Effect.",
        "clause_text": "any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_projections_miss_included": {
        "answer": true,
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_projections_miss_explanation": {
        "answer": "The failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period is excluded from the definition of Material Adverse Effect.",
        "clause_text": "The failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_other_custom_items_present": {
        "answer": true,
        "clause_text": "any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”));",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveout_other_custom_items": {
        "answer": [
          {
            "label": "Union Activity",
            "excerpt": "any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary"
          },
          {
            "label": "Regulatory Delays",
            "excerpt": "any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs"
          },
          {
            "label": "Legal Proceedings",
            "excerpt": "any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions"
          },
          {
            "label": "SEC Filing Delays",
            "excerpt": "the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders"
          },
          {
            "label": "Disclosure Controls and Procedures",
            "excerpt": "the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees"
          }
        ],
        "clause_text": "",
        "reference_section": ""
      },
      "standard_mae_carveouts_list": {
        "answer": "(i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions, the Carve-Out (including any action taken or omitted for the purpose of implementing the Carve-Out) or the terms of this Agreement (including the identity of Parent or any of its Affiliates or any communication by Parent or any of its Affiliates regarding the plans or intentions of Parent or any of its Affiliates with respect to the composition or conduct of the business of the Company or any Company Subsidiary), including the impact of any of the foregoing on the relationships, contractual or otherwise, of the Company or any Company Subsidiary with employees, labor unions, works councils, financing sources, customers, franchisees, suppliers, partners, resellers, contract manufacturers, distributors, licensors, licensees, Governmental Authorities, or other business or regulatory relationships (other than for purposes of any representation or warranty in Section 3.05, but subject to disclosures in Section 3.05 of the Company Disclosure Schedule, to the extent the purpose of such representation or warranty is to address the consequences resulting from the execution of this Agreement or the consummation of the Transactions and the other transactions contemplated hereby); (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates; (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy; (v) any domestic, foreign or global political, regulatory, or social condition (including any actual or potential sequester, stoppage, shutdown, default, or similar event or occurrence by or involving any Governmental Authority affecting a national or federal government as a whole), any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”)); (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (vii) any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary; (viii) any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement; (ix) Parent’s or Merger Sub’s breach of this Agreement; (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof; (xi) any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs; (xii) any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions; (xiii) any action taken by Parent or any of its Affiliates; (xiv) the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders; (xv) the matter set forth on Section A-1(xv) of the Company Disclosure Schedule (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); or (xvi) the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees, any (A) Legal Proceedings, (B) governmental investigations or inquiries, (C) penalties, sanctions, fines, injunctive relief, remediation, or any other civil sanction (in each case whether threatened, pending, deferred, or otherwise, and whether financial or otherwise), or (D) default or event of default under the Credit Agreement for failure to furnish the lenders and other parties thereto, or under the Indentures for failure to furnish the holders of the notes issued thereunder, with financial or other information required to be provided thereunder or any failure to file such information with the SEC; provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate (in which case the incremental materially disproportionate adverse effect or effects may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect).",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions, the Carve-Out (including any action taken or omitted for the purpose of implementing the Carve-Out) or the terms of this Agreement (including the identity of Parent or any of its Affiliates or any communication by Parent or any of its Affiliates regarding the plans or intentions of Parent or any of its Affiliates with respect to the composition or conduct of the business of the Company or any Company Subsidiary), including the impact of any of the foregoing on the relationships, contractual or otherwise, of the Company or any Company Subsidiary with employees, labor unions, works councils, financing sources, customers, franchisees, suppliers, partners, resellers, contract manufacturers, distributors, licensors, licensees, Governmental Authorities, or other business or regulatory relationships (other than for purposes of any representation or warranty in Section 3.05, but subject to disclosures in Section 3.05 of the Company Disclosure Schedule, to the extent the purpose of such representation or warranty is to address the consequences resulting from the execution of this Agreement or the consummation of the Transactions and the other transactions contemplated hereby); (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates; (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy; (v) any domestic, foreign or global political, regulatory, or social condition (including any actual or potential sequester, stoppage, shutdown, default, or similar event or occurrence by or involving any Governmental Authority affecting a national or federal government as a whole), any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”)); (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (vii) any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary; (viii) any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement; (ix) Parent’s or Merger Sub’s breach of this Agreement; (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof; (xi) any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs; (xii) any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions; (xiii) any action taken by Parent or any of its Affiliates; (xiv) the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders; (xv) the matter set forth on Section A-1(xv) of the Company Disclosure Schedule (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); or (xvi) the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees, any (A) Legal Proceedings, (B) governmental investigations or inquiries, (C) penalties, sanctions, fines, injunctive relief, remediation, or any other civil sanction (in each case whether threatened, pending, deferred, or otherwise, and whether financial or otherwise), or (D) default or event of default under the Credit Agreement for failure to furnish the lenders and other parties thereto, or under the Indentures for failure to furnish the holders of the notes issued thereunder, with financial or other information required to be provided thereunder or any failure to file such information with the SEC; provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate (in which case the incremental materially disproportionate adverse effect or effects may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect).",
        "reference_section": "Definition > Material Adverse Effect"
      }
    },
    "mae_carveback": {
      "mae_carveback_disproportionate_effects_included": {
        "answer": true,
        "clause_text": "provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate.",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveback_disproportionate_effects_explanation": {
        "answer": "any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate",
        "clause_text": "any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveback_additional_exceptions_included": {
        "answer": true,
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveback_additional_exceptions_explanation": {
        "answer": [
          "The underlying facts or occurrences giving rise to changes in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition.",
          "The underlying facts or occurrences giving rise to the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition.",
          "Any event, change, occurrence, or development referred to in clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate."
        ],
        "clause_text": "",
        "reference_section": ""
      },
      "mae_carveback_causation_based_analysis_included": {
        "answer": true,
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      },
      "mae_carveback_causation_based_analysis_explanation": {
        "answer": "The facts or occurrences giving rise to an excluded event may still be taken into account in determining whether a Material Adverse Effect has occurred, specifically for clauses (i) and (vi).",
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      }
    }
  },
  "non_solicitation": {
    "no_shop_clause": {
      "no_shop_clause_included": {
        "answer": true,
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal...",
        "reference_section": "Section 5.03 (a)"
      },
      "no_shop_claus_explanation": {
        "answer": "During the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal, (ii) engage in, continue, or otherwise participate in any discussion or negotiation regarding, or furnish to any other Person any non-public information in connection with, or for the purpose of knowingly encouraging or knowingly facilitating, an Acquisition Proposal, or (iii) enter into any letter of intent, acquisition agreement, agreement in principle, or similar agreement with respect to an Acquisition Proposal (other than an Acceptable Confidentiality Agreement in accordance with Section 5.03(b)).",
        "clause_text": "During the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal, (ii) engage in, continue, or otherwise participate in any discussion or negotiation regarding, or furnish to any other Person any non-public information in connection with, or for the purpose of knowingly encouraging or knowingly facilitating, an Acquisition Proposal, or (iii) enter into any letter of intent, acquisition agreement, agreement in principle, or similar agreement with respect to an Acquisition Proposal (other than an Acceptable Confidentiality Agreement in accordance with Section 5.03(b)).",
        "reference_section": "Section 5.03 (a)"
      }
    },
    "notice_of_competing_offer": {
      "notice_of_competing_offer_included": {
        "answer": true,
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal...",
        "reference_section": "Section 5.03 (c)"
      },
      "notice_of_competing_offer_explanation": {
        "answer": "The Company is required to notify the Parent of any Acquisition Proposal within forty-eight (48) hours, including the identity of the Person or group making such proposal, and provide a copy or summary of the material terms.",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "Section 5.03 (c)"
      }
    },
    "ongoing_update": {
      "ongoing_update_included": {
        "answer": true,
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "Section 5.03 (c)"
      },
      "ongoing_update_explanation": {
        "answer": "The Company is obligated to provide ongoing updates to the Buyer about any changes in status or negotiations relating to a competing offer.",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "Section 5.03 (c)"
      }
    },
    "superior_proposal_engagement": {
      "superior_proposal_engagement_included": {
        "answer": true,
        "clause_text": "if the Company Board determines in good faith, after consultation with its outside legal counsel and financial advisors, that such Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Offer, then the Company and its Representatives may (A) negotiate and enter into an Acceptable Confidentiality Agreement with the Person or Persons making such Acquisition Proposal and furnish, pursuant to any such Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Company to the Person or group of Persons who has made such Acquisition Proposal and their potential sources of financing and their respective Representatives; provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives and (y) any competitively sensitive information or data provided to such Person will be provided in a separate 'clean team room' and subject to customary 'clean team' arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel, and (B) engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and their potential sources of financing and their respective Representatives.",
        "reference_section": "Section 5.03 (b)"
      },
      "superior_proposal_engagement_explanation": {
        "answer": "The Company is authorized to engage with third parties if a Superior Proposal is received, provided the Company Board determines in good faith that the proposal constitutes or could lead to a Superior Offer.",
        "clause_text": "if the Company Board determines in good faith, after consultation with its outside legal counsel and financial advisors, that such Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Offer, then the Company and its Representatives may (A) negotiate and enter into an Acceptable Confidentiality Agreement with the Person or Persons making such Acquisition Proposal and furnish, pursuant to any such Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Company to the Person or group of Persons who has made such Acquisition Proposal and their potential sources of financing and their respective Representatives; provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives and (y) any competitively sensitive information or data provided to such Person will be provided in a separate \"clean team room\" and subject to customary \"clean team\" arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel, and (B) engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and their potential sources of financing and their respective Representatives.",
        "reference_section": "Section 5.03 (b)"
      }
    },
    "match_right": {
      "match_right_initial_included": {
        "answer": true,
        "clause_text": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "reference_section": "Section 6.01 (b) (i) (2)"
      },
      "match_right_initial_explanation": {
        "answer": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "clause_text": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "reference_section": "Section 6.01 (b) (i) (2)"
      },
      "match_right_amended_included": {
        "answer": false,
        "clause_text": "The provisions of this Section 6.01(b)(i) shall also apply to any material amendment to any Acquisition Proposal, which shall require a new Determination Notice and compliance with clause (D) above, except that, in each case, the references to five (5) days shall be deemed to be three (3) days;",
        "reference_section": "Section 6.01 (b) (i)"
      },
      "match_right_amended_explanation": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "adverse_recommendation_change": {
      "adverse_recommendation_change_superior_proposal_included": {
        "answer": true,
        "clause_text": "if the Company has received a written Acquisition Proposal... the Company Board may make a Company Adverse Change Recommendation... if and only if: (A) the Company Board determines in good faith... that such Acquisition Proposal is a Superior Offer;",
        "reference_section": "Section 6.01 (b) (i)"
      },
      "adverse_recommendation_change_superior_proposal_explanation": {
        "answer": "The Company Board is permitted to change its recommendation in response to a Superior Proposal if it determines in good faith, after consultation with financial advisors and outside legal counsel, that such Acquisition Proposal is a Superior Offer and that failure to do so would be inconsistent with fiduciary duties.",
        "clause_text": "if and only if: (A) the Company Board determines in good faith, after consultation with financial advisors and outside legal counsel, that such Acquisition Proposal is a Superior Offer; (B) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law;",
        "reference_section": "Section 6.01 (b) (i)"
      },
      "adverse_recommendation_change_intervening_event_included": {
        "answer": true,
        "clause_text": "other than in connection with an Acquisition Proposal, the Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law;",
        "reference_section": "Section 6.01 (b) (ii)"
      },
      "adverse_recommendation_change_intervening_event_explanation": {
        "answer": "The Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law; (B) the Company shall have given Parent a Determination Notice at least five (5) days prior to making any such Company Adverse Change Recommendation; and (C) (1) the Company shall have specified the Change in Circumstance in reasonable detail, (2) the Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3) after considering the outcome of any such negotiation and giving effect to any binding commitment made in writing by Parent, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation in response to such Change in Circumstance would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law.",
        "clause_text": "The Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law; (B) the Company shall have given Parent a Determination Notice at least five (5) days prior to making any such Company Adverse Change Recommendation; and (C) (1) the Company shall have specified the Change in Circumstance in reasonable detail, (2) the Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3) after considering the outcome of any such negotiation and giving effect to any binding commitment made in writing by Parent, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation in response to such Change in Circumstance would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law.",
        "reference_section": "Section 6.01 (b) (ii)"
      },
      "adverse_recommendation_change_timing": {
        "answer": "The Company Board must provide Parent with a Determination Notice at least five (5) days prior to making any Company Adverse Change Recommendation.",
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "Section 6.01 (b) (i)"
      }
    },
    "go_shop": {
      "go_shop_included": {
        "answer": false,
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal.",
        "reference_section": "Section 5.03 (a)"
      },
      "go_shop_explanation": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "buyer_diligence_access": {
      "buyer_diligence_access_included": {
        "answer": true,
        "clause_text": "provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives",
        "reference_section": "Section 5.03 (b)"
      },
      "buyer_diligence_access_explanation": {
        "answer": "The Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives.",
        "clause_text": "The Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives.",
        "reference_section": "Section 5.03 (b)"
      }
    },
    "recommendation_change_restriction": {
      "recommendation_change_restriction_included": {
        "answer": true,
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "Section 6.01 (b) (i)"
      },
      "recommendation_change_restriction_explanation": {
        "answer": "The agreement imposes procedural and timing-based restrictions on how the Company may change its recommendation.",
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "Section 6.01 (b) (i)"
      }
    }
  },
  "best_efforts": {
    "regulatory_efforts": {
      "effort_standard": {
        "answer": "Reasonable Best Efforts",
        "clause_text": "each of Parent, Merger Sub, and the Company and the members of their respective boards of directors shall use their respective reasonable best efforts to grant such approvals, and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable",
        "reference_section": "Section 6.07"
      },
      "effort_scope": {
        "answer": "RBE for HSR, FTC, DOJ, CMA, and other Requisite Regulatory Approvals",
        "clause_text": "the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions, so as to obtain such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under the HSR Act, in connection with any other Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws, and (B) to avoid the commencement of a Legal Proceeding by the FTC, the DOJ, any other Governmental Authority, or any other Person in connection with any Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws, and to avoid the entry of, or to effect the prompt dissolution of, any injunction, temporary restraining order, or other order in any Legal Proceeding that would otherwise have the effect of preventing or delaying the Closing, including, in each case, (i) negotiating, committing to, and effecting, by consent decree, hold separate order, or otherwise, the sale, lease, license, divestiture, or disposition of any asset, right, Contract, product line, product, technology or business of the Company, Parent, or any of their respective controlled Affiliates, (ii) terminating any existing relationship, contractual right, or obligation of the Company, Parent, or any of their respective controlled Affiliates, (iii) terminating any venture or other arrangement, (iv) creating any relationship, contractual right, or obligation of the Company, Parent, or any of their respective controlled Affiliates, (v) effectuating any other change or restructuring of the Company, Parent, or any of their respective controlled Affiliates, (vi) undertaking or agreeing to (or requesting or authorizing the Company or any Company Subsidiary to undertake, effective upon the Closing) any requirement or obligation to provide prior notice to, or obtain prior approval from, any Governmental Authority with respect to any transaction or any other matter, and (vii) otherwise taking or committing to take any action with respect to, or restricting the operations of, the assets, rights, Contracts, product lines, products, technologies, or businesses of the Company, Parent, or any of their respective controlled Affiliates; provided, however, (1) that in no event shall any Party or any of their respective controlled Affiliates be required to take or commit to take any such action, or agree to any such condition or restriction that is not conditioned upon the occurrence of the Closing, (2) neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent, and (3) at Parent's request, the Company shall, and shall cause its Subsidiaries to, take or commit to take any such action, or agree to any such condition or restriction, so long as it is conditioned upon the occurrence of the Closing.",
        "reference_section": "Section 6.02 (b)"
      }
    },
    "regulatory_fillings_hsr": {
      "hsr_required": {
        "answer": true,
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "Section 6.02 (c)"
      },
      "hsr_filing_deadline_days": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "hsr_notes": {
        "answer": "Must file within 20 business days of signing; filing required under HSR Act as a condition to closing.",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "Section 6.02 (c)"
      }
    },
    "regulatory_fillings_cfius": {
      "cfius_required": {
        "answer": false,
        "clause_text": "There is no clause explicitly referencing a CFIUS notice, declaration, approval requirement, or foreign investment review.",
        "reference_section": "Not applicable as there is no relevant section mentioning CFIUS."
      },
      "cfius_filing_deadline_days": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "cfius_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "regulatory_fillings_foreign": {
      "foreign_filling_notes": {
        "answer": "Foreign filings may be required under applicable non-U.S. laws",
        "clause_text": "Antitrust Laws means (a) the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, state antitrust Laws, and all other applicable Law and regulations (including non-U.S. Laws and regulations) issued by a Governmental Authority that are designed or intended to preserve or protect competition...",
        "reference_section": "Definition > Antitrust Laws"
      },
      "foreign_filling_required": {
        "answer": true,
        "clause_text": "Antitrust Laws means (a) the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, state antitrust Laws, and all other applicable Law and regulations (including non-U.S. Laws and regulations) issued by a Governmental Authority...",
        "reference_section": "Definition > Antitrust Laws"
      },
      "foreign_filling_deadline_days": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "divestiture_commitments": {
      "divestiture_required": {
        "answer": true,
        "clause_text": "the sale, lease, license, divestiture, or disposition of any asset, right, Contract, product line, product, technology or business of the Company, Parent, or any of their respective controlled Affiliates",
        "reference_section": "Section 6.02 (b)"
      },
      "divestiture_cap_target_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "divestiture_cap_buyer_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "litigation_commitments": {
      "litigation_requirement_status": {
        "answer": "No Mention",
        "clause_text": "",
        "reference_section": ""
      },
      "litigation_clause_scope": {
        "answer": "The Company controls litigation but must consult with Parent and cannot settle without written consent.",
        "clause_text": "The Company shall control any Transaction Litigation; provided that the Company will: (a) give Parent the reasonable opportunity to participate in the defense, settlement, or prosecution of any Transaction Litigation; (b) reasonably consult with Parent with respect to the defense, settlement and prosecution of any Transaction Litigation; and (c) consider in good faith Parent's advice with respect to any Transaction Litigation. The Company may not compromise, settle, or come to an arrangement regarding any Transaction Litigation unless Parent has consented thereto in writing (which consent shall not be unreasonably withheld, conditioned, or delayed).",
        "reference_section": "Section 6.05"
      },
      "required_to_litigate_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "withdrawal_and_timing_controls_withdrawal": {
      "withdrawal_control_type": {
        "answer": "mutual_consent_required",
        "clause_text": "provided, further, that if the Chief Executive Officers of the Parties cannot resolve any such disagreement, the final determination as to the appropriate course of action shall be made by Parent, acting reasonably after considering the comments and advice of the Company and its Representatives in good faith.",
        "reference_section": "Section 6.02 (e)"
      },
      "withdrawal_control_type_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "withdrawal_and_timing_controls_timing": {
      "timing_agreement_restriction": {
        "answer": false,
        "clause_text": "The provided excerpts do not contain any language explicitly restricting either party from entering into timing agreements under the HSR Act without the other party's consent.",
        "reference_section": "Section 6.02"
      },
      "timing_agreement_restriction_notes": {
        "answer": "The agreement outlines timing restrictions related to obtaining regulatory approvals and the lapse of waiting periods, including the requirement for Parent's prior written consent for certain actions by the Company.",
        "clause_text": "provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "Section 6.02 (a)"
      }
    },
    "remedy_actions_other": {
      "remedy_definitions_provided": {
        "answer": true,
        "clause_text": "Without limiting the obligations imposed under Section 6.02(a), the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions, so as to obtain such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under the HSR Act, in connection with any other Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws...",
        "reference_section": "Section 6.02 (b)"
      },
      "remedy_definition_text": {
        "answer": "Upon the terms and subject to the conditions set forth in this Agreement, each of the Parties shall, and shall cause their respective controlled Affiliates to, take, or cause to be taken, all actions, to file, or cause to be filed, all documents, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper, or advisable to consummate and make effective the Transactions as soon as reasonably practicable, including (i) the obtaining of all necessary, proper, or advisable actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods from Governmental Authorities and the making of all necessary, proper, or advisable registrations and filings and the taking of all steps as may be necessary or advisable to obtain any such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods by or from, or to avoid a Legal Proceeding by, any Governmental Authority in connection with any Requisite Regulatory Approvals, (ii) the obtaining of all necessary, proper, or advisable consents, authorizations, approvals, or waivers from third parties, (iii) the submission of all notifications, and obtaining of all consents, authorizations, or approvals of any filings or applications, that may be required to obtain, maintain or transfer any Governmental Authorizations related to applicable Healthcare Laws; and (iv) the execution and delivery of any additional instrument necessary, proper, or advisable to consummate the Transactions; provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, each of the Parties shall, and shall cause their respective controlled Affiliates to, take, or cause to be taken, all actions, to file, or cause to be filed, all documents, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper, or advisable to consummate and make effective the Transactions as soon as reasonably practicable, including (i) the obtaining of all necessary, proper, or advisable actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods from Governmental Authorities and the making of all necessary, proper, or advisable registrations and filings and the taking of all steps as may be necessary or advisable to obtain any such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods by or from, or to avoid a Legal Proceeding by, any Governmental Authority in connection with any Requisite Regulatory Approvals, (ii) the obtaining of all necessary, proper, or advisable consents, authorizations, approvals, or waivers from third parties, (iii) the submission of all notifications, and obtaining of all consents, authorizations, or approvals of any filings or applications, that may be required to obtain, maintain or transfer any Governmental Authorizations related to applicable Healthcare Laws; and (iv) the execution and delivery of any additional instrument necessary, proper, or advisable to consummate the Transactions; provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "Section 6.02 (a)"
      },
      "remedy_action_limitations_exists": {
        "answer": true,
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, in no event shall Parent or any of its controlled Affiliates be required to (i) take any action that would result in, or would reasonably be expected to result in, individually or in the aggregate, an effect that is adverse and material on either (A) the capacity that would otherwise be available to Carve-Out Purchaser and its controlled Affiliates at the Carve-Out Business after the Closing or (B) Parent and its controlled Affiliates, taken as a whole, assuming the Closing has occurred but measured on a scale relative to the size of the Company and the Company Subsidiaries (other than the Carve-Out Business) or (ii) take any action, including divesting, licensing, holding separate, otherwise transferring or disposing of, or allowing a third party to utilize, with respect to (A) any portion of the Carve-Out Purchaser's or any of its controlled Affiliates' (other than the Company and its controlled Affiliates) (w) production assets, (x) product lines, (y) research, clinical or pharmaceutical products or (z) other material assets (with 'material' measured on a scale relative to the size of the Carve-Out Business with respect to the Carve-Out Purchaser and its controlled Affiliates) or (B) without limiting the foregoing clause (A) of this clause (ii), any portion of Investor's, Parent's or any of its or their controlled Affiliates' (other than the Carve-Out Purchaser and its controlled Affiliates and the Company and its controlled Affiliates) assets (any of the actions described in clauses (i)-(ii), a 'Burdensome Condition').",
        "reference_section": "Section 6.02 (b)"
      },
      "remedy_action_limitations_text": {
        "answer": "The agreement limits the obligation to take remedy or divestiture actions if such actions would result in a 'Burdensome Condition'.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, in no event shall Parent or any of its controlled Affiliates be required to (i) take any action that would result in, or would reasonably be expected to result in, individually or in the aggregate, an effect that is adverse and material on either (A) the capacity that would otherwise be available to Carve-Out Purchaser and its controlled Affiliates at the Carve-Out Business after the Closing or (B) Parent and its controlled Affiliates, taken as a whole, assuming the Closing has occurred but measured on a scale relative to the size of the Company and the Company Subsidiaries (other than the Carve-Out Business) or (ii) take any action, including divesting, licensing, holding separate, otherwise transferring or disposing of, or allowing a third party to utilize, with respect to (A) any portion of the Carve-Out Purchaser's or any of its controlled Affiliates' (other than the Company and its controlled Affiliates) (w) production assets, (x) product lines, (y) research, clinical or pharmaceutical products or (z) other material assets (with 'material' measured on a scale relative to the size of the Carve-Out Business with respect to the Carve-Out Purchaser and its controlled Affiliates) or (B) without limiting the foregoing clause (A) of this clause (ii), any portion of Investor's, Parent's or any of its or their controlled Affiliates' (other than the Carve-Out Purchaser and its controlled Affiliates and the Company and its controlled Affiliates) assets (any of the actions described in clauses (i)-(ii), a 'Burdensome Condition').",
        "reference_section": "Section 6.02 (b)"
      }
    },
    "transaction_interference": {
      "restriction_on_other_transactions": {
        "answer": true,
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal...",
        "reference_section": "Section 5.03 (a)"
      },
      "interference_clause_text": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "second_request_certification": {
      "second_request_certification_deadline_specified": {
        "answer": false,
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act.",
        "reference_section": "Section 6.02 (d)"
      },
      "second_request_certification_certification_timeline_notes": {
        "answer": "as promptly as reasonably practicable",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement...",
        "reference_section": "Section 6.02 (c)"
      },
      "second_request_certification_responsibility_party": {
        "answer": "Both",
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Authority in connection with such applications or filings for the Transactions.",
        "reference_section": "Section 6.02 (d)"
      }
    },
    "ftc_warning_letter_handling": {
      "ftc_warning_letter_handling_addressed": {
        "answer": false,
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Authority in connection with such applications or filings for the Transactions.",
        "reference_section": "Section 6.02 (d)"
      },
      "ftc_warning_letter_handling_notes": {
        "answer": "Not addressed",
        "clause_text": "",
        "reference_section": ""
      },
      "ftc_warning_letter_handling_effect_on_closing_condition": {
        "answer": "Silent",
        "clause_text": "",
        "reference_section": ""
      },
      "ftc_warning_letter_handling_addressed_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "other_timing_controls": {
      "other_timing_controls_deadlines_specified": {
        "answer": [
          "Company Stockholders' Meeting to occur within 45 days following the mailing of the Proxy Statement.",
          "Adjournments, recesses, or postponements of the Company Stockholders' Meeting shall be for periods of no more than 10 business days each unless agreed in writing by the Company and Parent.",
          "Written consent of Parent required for adjournment, recess, or postponement beyond two occasions."
        ],
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the \"Company Stockholders' Meeting\")... provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each... provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "Section 5.05"
      }
    },
    "novel_or_unstructured_regulatory_clauses": {
      "novel_or_unstructured_regulatory_clauses_items": {
        "answer": [
          {
            "summary": "The clause imposes a condition that neither the Company nor its Subsidiaries may take or commit to any action, or agree to any condition or restriction, without Parent's prior written consent.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)",
            "review_required": true
          },
          {
            "summary": "The clause states that Parent shall not be required to take any action that would result in a material adverse effect on the Carve-Out Business or Parent and its controlled Affiliates.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)",
            "review_required": true
          },
          {
            "summary": "The clause requires the Company to provide Parent with notice and opportunity to review and comment on responses to any Regulatory Matter.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (g)",
            "review_required": true
          }
        ],
        "clause_text": "",
        "reference_section": ""
      }
    },
    "prior_approval_commitment": {
      "prior_approval_commitment_addressed": {
        "answer": true,
        "clause_text": "undertaking or agreeing to (or requesting or authorizing the Company or any Company Subsidiary to undertake, effective upon the Closing) any requirement or obligation to provide prior notice to, or obtain prior approval from, any Governmental Authority with respect to any transaction or any other matter",
        "reference_section": "Section 6.02 (b)"
      },
      "prior_approval_commitment_obligations_summary": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "regulatory_process_control_discretion": {
      "regulatory_process_control_discretion": {
        "answer": "Parent",
        "clause_text": "In no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "Section 6.02 (a)"
      },
      "parent_has_sole_discretion_excluding_remedies": {
        "answer": false,
        "clause_text": "The Parties shall jointly develop, determine and cooperate with one another with respect to (i) the strategy for obtaining any necessary clearances or approvals under the HSR Act and any other Antitrust Laws...",
        "reference_section": "Section 6.02 (e)"
      }
    },
    "no_limitations_on_buyer_remedies": {
      "no_limitations_on_buyer_remedies_value": {
        "answer": false,
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, in no event shall Parent or any of its controlled Affiliates be required to (i) take any action that would result in, or would reasonably be expected to result in, individually or in the aggregate, an effect that is adverse and material on either (A) the capacity that would otherwise be available to Carve-Out Purchaser and its controlled Affiliates at the Carve-Out Business after the Closing or (B) Parent and its controlled Affiliates, taken as a whole...",
        "reference_section": "Section 6.02 (b)"
      },
      "no_limitations_on_buyer_remedies_inferred_hohw": {
        "answer": false,
        "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date...",
        "reference_section": "Section 7.03"
      },
      "no_limitations_on_buyer_remedies_explanation": {
        "answer": "Not applicable",
        "clause_text": "",
        "reference_section": ""
      },
      "no_limitations_on_buyer_remedies_notes": {
        "answer": "Not Found",
        "clause_text": "",
        "reference_section": ""
      },
      "no_limitations_on_buyer_remedies_inferred_hohw_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "no_limitations_on_buyer_remedies_materiality_basis": {
        "answer": "relative to Buyer",
        "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: ... without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
        "reference_section": "Section 7.03"
      },
      "materiality_definition_text": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "refiling_commitment": {
      "refiling_commitment_required": {
        "answer": true,
        "clause_text": "Without limiting the obligations imposed under Section 6.02(a), the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions, so as to obtain such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under the HSR Act.",
        "reference_section": "Section 6.02 (b)"
      },
      "refiling_commitment_required_notes": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "refiling_commitment_max_refiles": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "refiling_commitment_max_refiles_notes": {
        "answer": "Not Specified",
        "clause_text": "",
        "reference_section": ""
      },
      "refiling_commitment_max_refiles_specification_status": {
        "answer": "Not Specified",
        "clause_text": "The excerpts provided do not mention the number of HSR refilings.",
        "reference_section": "Section 6.02"
      }
    },
    "union_item": {
      "union_efforts_required": {
        "answer": false,
        "clause_text": "Except as would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect, there is no, and since June 30, 2022, there has not been, any labor strike, slowdown or any other concerted interference with normal operations, work stoppage, lockout, job action, picketing of any nature, labor dispute, organizational campaign, union organizing activity or any similar activity or dispute with respect to any employees of the Company or any Company Subsidiary pending or, to the knowledge of the Company, threatened against or affecting the business of the Company or any Company Subsidiary.",
        "reference_section": "Section 3.19"
      },
      "union_consultation_timeframe": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "union_agreement_obligation_summary": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "regulatory_strategy_control_rights": {
      "regulatory_strategy_control_rights": {
        "answer": "Parent",
        "clause_text": "the final determination as to the appropriate course of action shall be made by Parent, acting reasonably after considering the comments and advice of the Company and its Representatives in good faith.",
        "reference_section": "Section 6.02 (e)"
      }
    },
    "regulatory_delay_control_rights": {
      "regulatory_delay_control_rights": {
        "answer": "Parent",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "Section 6.02 (b)"
      }
    },
    "remedy_consent_required_by_target": {
      "remedy_consent_required_by_target": {
        "answer": "The agreement requires the target to obtain written consent from the acquirer before taking any regulatory remedial actions.",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "Section 6.02 (b)"
      }
    },
    "regulatory_review_discretion_rights": {
      "regulatory_review_discretion_rights": {
        "answer": "Parent holds discretion over regulatory filings and procedural decisions.",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "Section 6.02 (b)"
      }
    }
  },
  "termination": {
    "outside_date": {
      "primary_date": {
        "answer": "February 5, 2025",
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (a) by the mutual written consent of the Company and Parent; (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the \"End Date\");",
        "reference_section": "Section 8.01"
      }
    },
    "extension": {
      "extension_list": {
        "answer": "1. Extension Length – 3 months; Who Grants the Extension – Automatic; Conditions to Extend – All conditions set forth in Section 7.01, Section 7.02, and Section 7.03 must be satisfied or waived, except for certain specified conditions; Termination Restrictions Due to Breach – Yes, the party seeking to terminate must not have breached or failed to perform in any material respect its obligations under the Agreement in any manner that shall have principally caused the failure to consummate the Merger on or before such Test Date.",
        "clause_text": "provided that such date shall automatically be extended by three (3) months on four (4) occasions (the date of such occasion, a 'Test Date') if, as of such date (or a subsequent Test Date), all conditions set forth in Section 7.01, Section 7.02, and Section 7.03 shall have been satisfied or waived...; provided further that...the Party seeking to terminate this Agreement...shall not have breached or failed to perform in any material respect its obligations under this Agreement in any manner that shall have principally caused the failure to consummate the Merger on or before such Test Date.",
        "reference_section": "Section 8.01"
      }
    },
    "termination_fee": {
      "termination_fee": {
        "answer": "$344,800,000",
        "clause_text": "then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above;",
        "reference_section": "Section 8.03 (a)"
      }
    },
    "reverse_termination_fee": {
      "reverse_termination_fee": {
        "answer": 584400000,
        "clause_text": "Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination;",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "reverse_termination_fee_exist": {
      "reverse_termination_fee_exist": {
        "answer": true,
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) ... then Parent shall pay ... a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination;",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "termination_fee_superior_proposal": {
      "termination_fee_superior_proposal_exists": {
        "answer": true,
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g)...then the Company shall pay...a fee of $344,800,000 in cash (the 'Company Termination Fee').",
        "reference_section": "Section 8.03 (a)"
      },
      "termination_fee_superior_proposal": {
        "answer": "344800000",
        "clause_text": "then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above;",
        "reference_section": "Section 8.03 (a)"
      }
    },
    "termination_fee_company_shareholder_approval": {
      "termination_fee_company_shareholder_approval_failure_exists": {
        "answer": true,
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) ... this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) ... then the Company shall pay ... a fee of $344,800,000 in cash (the 'Company Termination Fee').",
        "reference_section": "Section 8.03 (a)"
      },
      "termination_fee_company_shareholder_approval_failure": {
        "answer": "Not specified",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) (A) after the date of this Agreement, an Acquisition Proposal is publicly proposed or publicly disclosed prior to, and not publicly withdrawn without qualification at least three (3) business days prior to, the Company Stockholders' Meeting or the breach giving rise to the right to terminate this Agreement pursuant to Section 8.01(f), as applicable, (B) this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f) and (C) concurrently with or within twelve (12) months after such termination, (x) the Company shall have entered into a definitive agreement providing for an Acquisition Proposal (which Acquisition Proposal is subsequently consummated, whether during or following such twelve (12)-month period) or (y) an Acquisition Proposal is consummated (in the case of each of clauses (x) and (y), whether or not involving the same Acquisition Proposal which was made prior to the termination of this Agreement), then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above; it being understood that (x) for all purposes of clause (iii) above and the application of this Section 8.03(a), all references to twenty percent (20%) in the definition of \"Acquisition Proposal\" shall be deemed to be references to \"more than fifty percent (50%)\" and (y) in no event shall the Company be required to pay the Company Termination Fee on more than one occasion.",
        "reference_section": "Section 8.03 (a)"
      }
    },
    "reverse_termination_fee_shareholder_approval": {
      "reverse_termination_fee_shareholder_approval_failure_exists": {
        "answer": false,
        "clause_text": "No vote of Parent's stockholders is necessary to approve Parent's execution of this Agreement or the consummation of the Transactions.",
        "reference_section": "Section 4.04"
      },
      "reverse_termination_fee_shareholder_approval_failure": {
        "answer": "Not specified",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination; it being understood that in no event shall Parent be required to pay the Parent Termination Fee on more than one occasion.",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "termination_rights": {
      "mutual_termination_rights": {
        "answer": [
          "by either the Company or Parent if the Effective Time shall not have occurred on or before February 5, 2025",
          "by either the Company or Parent if any Governmental Authority shall have issued a Legal Restraint, and such Legal Restraint shall have become final and nonappealable",
          "by either the Company or Parent if the Company Stockholders' Meeting (including any adjournment, recess, or postponement thereof) shall have concluded and the Required Company Stockholder Vote contemplated by this Agreement shall not have been obtained following a vote thereon having been taken"
        ],
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025... (c) by either the Company or Parent if any Governmental Authority shall have issued a Legal Restraint, and such Legal Restraint shall have become final and nonappealable; (d) by either the Company or Parent if the Company Stockholders' Meeting... shall not have been obtained following a vote thereon having been taken;",
        "reference_section": "Section 8.01"
      },
      "parent_termination_rights": {
        "answer": [
          "by Parent if the Company shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.03(a) or Section 7.03(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following Parent's delivery of written notice to the Company stating Parent's intention to terminate this Agreement pursuant to this Section 8.01(f) and the basis for such termination; provided that Parent or Merger Sub is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.02(a), or Section 7.02(b);",
          "by Parent if the Company Board shall have effected a Company Adverse Change Recommendation pursuant to Section 6.01(b)."
        ],
        "clause_text": "by Parent if the Company shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.03(a) or Section 7.03(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following Parent's delivery of written notice to the Company stating Parent's intention to terminate this Agreement pursuant to this Section 8.01(f) and the basis for such termination; provided that Parent or Merger Sub is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.02(a), or Section 7.02(b); by Parent if the Company Board shall have effected a Company Adverse Change Recommendation pursuant to Section 6.01(b).",
        "reference_section": "Section 8.01"
      },
      "company_termination_rights": {
        "answer": [
          "by the Company if Parent or Merger Sub shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.02(a) or Section 7.02(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following the Company's delivery of written notice to Parent stating the Company's intention to terminate this Agreement pursuant to this Section 8.01(e) and the basis for such termination; provided that the Company is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.03(a), or Section 7.03(b);",
          "by the Company prior to the time the Required Company Stockholder Vote is obtained, in order to enter into an agreement providing for a Superior Offer, in accordance with Section 6.01(b);"
        ],
        "clause_text": "by the Company if Parent or Merger Sub shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.02(a) or Section 7.02(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following the Company's delivery of written notice to Parent stating the Company's intention to terminate this Agreement pursuant to this Section 8.01(e) and the basis for such termination; provided that the Company is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.03(a), or Section 7.03(b); by the Company prior to the time the Required Company Stockholder Vote is obtained, in order to enter into an agreement providing for a Superior Offer, in accordance with Section 6.01(b);",
        "reference_section": "Section 8.01"
      }
    },
    "termination_fee_events": {
      "company_termination_fee_events": {
        "answer": [
          "The Company shall have terminated this Agreement pursuant to Section 8.01(g)",
          "Parent shall have terminated this Agreement pursuant to Section 8.01(h)",
          "An Acquisition Proposal is publicly proposed or disclosed and not withdrawn before the Company Stockholders' Meeting, the Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f), and within twelve months after such termination, the Company enters into or consummates an Acquisition Proposal"
        ],
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) (A) after the date of this Agreement, an Acquisition Proposal is publicly proposed or publicly disclosed prior to, and not publicly withdrawn without qualification at least three (3) business days prior to, the Company Stockholders' Meeting or the breach giving rise to the right to terminate this Agreement pursuant to Section 8.01(f), as applicable, (B) this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f) and (C) concurrently with or within twelve (12) months after such termination, (x) the Company shall have entered into a definitive agreement providing for an Acquisition Proposal (which Acquisition Proposal is subsequently consummated, whether during or following such twelve (12)-month period) or (y) an Acquisition Proposal is consummated",
        "reference_section": "Section 8.03 (a)"
      },
      "parent_reverse_termination_fee_events": {
        "answer": [
          "If Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b)"
        ],
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination; it being understood that in no event shall Parent be required to pay the Parent Termination Fee on more than one occasion.",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "reimbursement_obligations": {
      "target_reimbursement_obligations": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "parent_reimbursement_obligations": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "regulatory_termination_fee": {
      "regulatory_termination_fee": {
        "answer": "$584,400,000",
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws)... then Parent shall pay... a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination;",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "failure_to_close_fee": {
      "failure_to_close_fee": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "reverse_termination_fee_regulatory": {
      "reverse_termination_fee_regulatory": {
        "answer": "$584,400,000",
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination;",
        "reference_section": "Section 8.03 (b)"
      }
    },
    "extend_or_terminate_limitation_due_to_breach": {
      "extend_or_terminate_limitation_due_to_breach": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "ordinary_course": {
    "company_ordinary_course_covenant": {
      "company_conduct_covenant_summary": {
        "answer": "During the Pre-Closing Period, the Company is required to use commercially reasonable efforts to conduct its business in all material respects in the ordinary course and to preserve its business organization and relationships, except as permitted by the Agreement or with Parent's consent.",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed), (y) for any action taken reasonably and in good faith in response to COVID-19 or COVID-19 Measures or (z) as set forth in Section 5.02 of the Company Disclosure Schedule, the Company shall, and shall cause the Company Subsidiaries to, use (i) commercially reasonable efforts to conduct its business in all material respects in the ordinary course and (ii) use commercially reasonable efforts to preserve intact its current business organization and to preserve its relationships with key employees and others having significant business dealings with the Company or any Company Subsidiary;",
        "reference_section": "Section 5.02 (a)"
      }
    },
    "parent_ordinary_course_covenant": {
      "parent_conduct_covenant_summary": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "board_approval": {
    "board_approval": {
      "target_board_approval": {
        "answer": true,
        "clause_text": "The Company Board (at a meeting duly called and held) on or prior to the date of this Agreement has: (a) unanimously determined that the Merger is advisable and fair to, and in the best interests of, the Company and its stockholders; (b) unanimously authorized and approved the execution, delivery, and performance of this Agreement by the Company and unanimously approved the Merger; and (c) unanimously recommended the adoption of this Agreement by the holders of Company Common Stock and directed that this Agreement be submitted for adoption by the Company stockholders at the Company Stockholders' Meeting.",
        "reference_section": "Section 3.04"
      },
      "target_board_unanimous": {
        "answer": true,
        "clause_text": "The Company Board (at a meeting duly called and held) on or prior to the date of this Agreement has: (a) unanimously determined that the Merger is advisable and fair to, and in the best interests of, the Company and its stockholders; (b) unanimously authorized and approved the execution, delivery, and performance of this Agreement by the Company and unanimously approved the Merger; and (c) unanimously recommended the adoption of this Agreement by the holders of Company Common Stock and directed that this Agreement be submitted for adoption by the Company stockholders at the Company Stockholders' Meeting.",
        "reference_section": "Section 3.04"
      },
      "acquirer_board_approval": {
        "answer": true,
        "clause_text": "WHEREAS, the boards of directors of Parent and Merger Sub have approved the execution, delivery, and performance of this Agreement and the consummation of the Transactions, including the Merger, and declared it advisable for Parent and Merger Sub, respectively, to enter into this Agreement;",
        "reference_section": "ARTICLE Preamble"
      },
      "acquirer_board_unanimous": {
        "answer": false,
        "clause_text": "WHEREAS, the boards of directors of Parent and Merger Sub have approved the execution, delivery, and performance of this Agreement and the consummation of the Transactions, including the Merger, and declared it advisable for Parent and Merger Sub, respectively, to enter into this Agreement;",
        "reference_section": "ARTICLE Preamble"
      }
    }
  },
  "party_details": {
    "acquirer": {
      "acquirer": {
        "answer": "Creek Parent, Inc.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      "parent_entity_details": {
        "answer": "Creek Parent, Inc.",
        "clause_text": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\")",
        "reference_section": "ARTICLE Preamble"
      }
    },
    "target": {
      "target": {
        "answer": "Catalent, Inc.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    },
    "guarantor": {
      "guarantor_present": {
        "answer": true,
        "clause_text": "The Limited Guarantee is (i) a legal, valid, and binding obligation of the Investor, (ii) enforceable against the Investor in accordance with its terms, and (iii) in full force and effect, subject, in the case of clauses (i) and (ii), to the effect of any Enforceability Exceptions.",
        "reference_section": "Section 4.07 (e)"
      },
      "guarantor_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "subsidiaries": {
      "target_subsidiaries_present": {
        "answer": false,
        "clause_text": "The Company hereby represents and warrants to Parent and Merger Sub as follows...",
        "reference_section": "Section 3.01"
      },
      "target_subsidiaries": {
        "answer": "No target subsidiaries explicitly involved in the merger structure are mentioned.",
        "clause_text": "The Company hereby represents and warrants to Parent and Merger Sub as follows...",
        "reference_section": "Section 3.01"
      },
      "acquirer_subsidiaries_present": {
        "answer": true,
        "clause_text": "Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged in any business activity or conducted any operation other than in connection with the Transactions and those incident to its formation.",
        "reference_section": "Section 4.02"
      },
      "acquirer_subsidiaries": {
        "answer": "[{ \"name\": \"Creek Merger Sub, Inc.\", \"clause_reference\": \"ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.02 Merger Sub\", \"role\": \"Wholly owned merger vehicle used to merge with the target\" }]",
        "clause_text": "Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged in any business activity or conducted any operation other than in connection with the Transactions and those incident to its formation.",
        "reference_section": "Section 4.02"
      }
    },
    "transaction": {
      "transaction_type": {
        "answer": "Reverse Triangular Merger",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub shall merge with and into the Company, whereupon the separate corporate existence of Merger Sub shall cease, and the Company shall continue its corporate existence under the laws of the State of Delaware (\"Delaware Law\") as the Surviving Corporation.",
        "reference_section": "Section 1.01"
      },
      "transaction_structure_notes": {
        "answer": "Merger Sub shall merge with and into the Company, with the Company continuing its corporate existence as the Surviving Corporation.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub shall merge with and into the Company, whereupon the separate corporate existence of Merger Sub shall cease, and the Company shall continue its corporate existence under the laws of the State of Delaware (\"Delaware Law\") as the Surviving Corporation.",
        "reference_section": "Section 1.01"
      }
    },
    "merger_sub_details": {
      "merger_sub_details": {
        "answer": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent",
        "clause_text": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\")",
        "reference_section": "ARTICLE Preamble"
      }
    }
  },
  "closing_mechanics": {
    "target_date": {
      "target_date": {
        "answer": "3 business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "Section 1.02"
      }
    },
    "marketing_period": {
      "has_marketing_period": {
        "answer": false,
        "clause_text": "The provided excerpts do not contain any reference to a 'Marketing Period'.",
        "reference_section": "No specific section references 'Marketing Period' in the provided excerpts."
      },
      "marketing_period_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "inside_date": {
      "has_inside_date": {
        "answer": false,
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (a) by the mutual written consent of the Company and Parent; (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the 'End Date');",
        "reference_section": "Section 8.01"
      },
      "inside_date_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "specific_performance": {
    "specific_performance": {
      "specific_performance_available": {
        "answer": true,
        "clause_text": "The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform its obligations under the provisions of this Agreement in accordance with its terms or otherwise breaches such provisions... the Parties shall be entitled to an injunction or injunctions, specific performance, or other non-monetary equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof...",
        "reference_section": "Section 9.05 (c)"
      },
      "specific_performance_parties": {
        "answer": "Parent, Company",
        "clause_text": "Subject to the following sentence, (i) the Parties shall be entitled to an injunction or injunctions, specific performance, or other non-monetary equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Chosen Courts without proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement...",
        "reference_section": "Section 9.05 (c)"
      },
      "specific_performance_limitations": {
        "answer": "The right to seek specific performance is subject to certain limitations, including the condition that the Company Termination Fee has not been paid when due and owing.",
        "clause_text": "Except if the Company Termination Fee has been paid when due and owing pursuant to Section 8.03, no Party shall oppose the granting of an injunction, specific performance, or other equitable relief on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or equity.",
        "reference_section": "Section 9.05 (c)"
      },
      "specific_performance_financing_condition": {
        "answer": false,
        "clause_text": "The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform its obligations under the provisions of this Agreement in accordance with its terms or otherwise breaches such provisions.",
        "reference_section": "Section 9.05 (c)"
      },
      "specific_performance_financing_details": {
        "answer": "The specific performance of the obligations under the Equity Commitment Letter is conditioned on the funding of the Equity Financing.",
        "clause_text": "The Equity Commitment Letter provides, and will continue to provide, that the Company is an express third-party beneficiary of the Equity Commitment Letter, including with respect to specific performance of the parties' obligations therein.",
        "reference_section": "Section 4.07 (d)"
      }
    }
  },
  "confidentiality_and_clean_room": {
    "confidentiality": {
      "confidentiality_exists": {
        "answer": true,
        "clause_text": "provided that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect; provided, further, that, if the Effective Time occurs, the Confidentiality Agreement shall automatically terminate and be of no further force and effect.",
        "reference_section": "Section 9.04"
      },
      "confidentiality_agreement_date": {
        "answer": "October 27, 2023",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the \"Confidentiality Agreement\").",
        "reference_section": "Section 5.01 (b)"
      },
      "confidentiality_obligation_termination_date": {
        "answer": "The confidentiality obligations are perpetual and extend post-termination.",
        "clause_text": "The Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect, in each case, in accordance with its terms.",
        "reference_section": "Section 8.02"
      },
      "confidentiality_amendment_exists": {
        "answer": false,
        "clause_text": "provided that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect; provided, further, that, if the Effective Time occurs, the Confidentiality Agreement shall automatically terminate and be of no further force and effect.",
        "reference_section": "Section 9.04"
      },
      "confidentiality_amendment_date": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "clean_room": {
      "clean_room_exists": {
        "answer": false,
        "clause_text": "The provided document excerpts do not mention a Clean Room or Clean Team arrangement.",
        "reference_section": "confidentiality_and_clean_room > clean_room"
      },
      "clean_room_signing_date": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "clean_room_start_date": {
        "answer": "October 27, 2023",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the 'Confidentiality Agreement').",
        "reference_section": "Section 5.01 (b)"
      },
      "clean_room_end_date": {
        "answer": "Closing",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "Section 1.02"
      },
      "clean_room_scope_restrictions": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "clean_room_protection_clause_present": {
        "answer": true,
        "clause_text": "any competitively sensitive information or data provided to such Person will be provided in a separate 'clean team room' and subject to customary 'clean team' arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel",
        "reference_section": "Section 5.03 (b)"
      },
      "clean_room_protection_clause_summary": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "complex_consideration_and_dividends": {
    "deal_consideration": {
      "deal_consideration_overview": {
        "answer": "$63.50 per Share in cash",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "deal_consideration_details": {
        "answer": "$63.50 per Share in cash",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "is_all_cash_deal": {
        "answer": true,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      }
    },
    "proration": {
      "proration_exists": {
        "answer": false,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the \"Company Common Stock,\" and each, a \"Share\") that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the \"Merger Consideration\").",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "proration_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "election": {
      "election_exists": {
        "answer": false,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the \"Company Common Stock,\" and each, a \"Share\") that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the \"Merger Consideration\").",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "election_details": {
        "answer": "No election is permitted and consideration is fixed.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      }
    },
    "cvr": {
      "cvr_exists": {
        "answer": false,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the 'Company Common Stock,' and each, a 'Share') that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "cvr_details": {
        "answer": "NA",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "ticking_fees": {
      "ticking_fees_exists": {
        "answer": false,
        "clause_text": "The provided excerpts do not contain any reference to ticking fees or similar provisions.",
        "reference_section": "Section 8.03"
      },
      "ticking_fees_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "contingent_payments": {
      "contingent_payments_exists": {
        "answer": true,
        "clause_text": "Indebtedness means... (e) any indebtedness for the deferred purchase price of property, or services with respect to which a Person is liable, including earnouts, holdbacks, and similar deferred payment obligations...",
        "reference_section": "Definition > Indebtedness"
      },
      "contingent_payments_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "company_dividends": {
      "company_dividends_can_pay": {
        "answer": false,
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed), (y) for any action taken reasonably and in good faith in response to COVID-19 or COVID-19 Measures or (z) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock (including the Company Common Stock)...",
        "reference_section": "Section 5.02 (b) (i)"
      },
      "company_dividends_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "parent_dividends": {
      "parent_dividends_can_pay": {
        "answer": false,
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed) or (y) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock...",
        "reference_section": "Section 5.02 (b) (i)"
      },
      "parent_dividends_details": {
        "answer": "No Dividends Allowed",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed) or (y) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock (including the Company Common Stock)...",
        "reference_section": "Section 5.02 (b) (i)"
      }
    },
    "collar": {
      "collar_exists": {
        "answer": false,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company... shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "collar_details": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "exchange_ratio": {
      "exchange_ratio_exists": {
        "answer": false,
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company ... shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "Section 2.01 (a) (i)"
      },
      "exchange_ratio_summary": {
        "answer": "NA",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "exchange_ratio_adjustment": {
      "exchange_ratio_adjustment_exists": {
        "answer": true,
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "Section 2.01 (c)"
      },
      "exchange_ratio_adjustment": {
        "answer": "The exchange ratio adjustment mechanism is tied to changes in the number of shares due to stock dividends, subdivisions, reorganizations, reclassifications, recapitalizations, stock splits, reverse stock splits, combinations, or exchanges of shares, with the Merger Consideration being equitably adjusted to proportionally reflect such changes.",
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "Section 2.01 (c)"
      }
    },
    "dividend_adjustment_mechanism": {
      "dividend_adjustment_mechanism_exists": {
        "answer": true,
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "Section 2.01 (c)"
      },
      "dividend_adjustment_mechanism": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "law_and_jurisdiction": {
    "governing_law": {
      "governing_law_exists": {
        "answer": true,
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "Section 9.05 (a)"
      },
      "governing_law_jurisdiction": {
        "answer": "Delaware",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "Section 9.05 (a)"
      }
    },
    "incorporation_details": {
      "parent_incorporation_details": {
        "answer": "a Delaware corporation",
        "clause_text": "AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      "company_incorporation_details": {
        "answer": "a corporation duly organized, validly existing, and in good standing under Delaware Law",
        "clause_text": "The Company is a corporation duly organized, validly existing, and in good standing under Delaware Law and has all necessary power and authority to (i) conduct its business in the manner in which its business is currently being conducted and (ii) own and use its assets in the manner in which its assets are currently owned and used.",
        "reference_section": "Section 3.01 (a)"
      }
    },
    "mae_interpretation_jurisdiction": {
      "mae_interpretation_jurisdiction_exists": {
        "answer": true,
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "Section 9.05 (a)"
      },
      "mae_interpretation_jurisdiction": {
        "answer": "Delaware",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "Section 9.05 (a)"
      }
    },
    "financing_jurisdiction": {
      "financing_jurisdiction_exists": {
        "answer": true,
        "clause_text": "Subject to Section 9.05(d), in any action or Legal Proceeding arising out of or relating to this Agreement or the Transactions (including any amount due or payable in connection therewith or any matter arising out of or relating to the termination of either of them), each of the Parties irrevocably and unconditionally (i) consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware...",
        "reference_section": "Section 9.05 (b)"
      },
      "financing_jurisdiction": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "arbitration_clause": {
      "arbitration_clause_exists": {
        "answer": false,
        "clause_text": "Subject to Section 9.05(d), in any action or Legal Proceeding arising out of or relating to this Agreement or the Transactions... each of the Parties irrevocably and unconditionally (i) consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware...",
        "reference_section": "Section 9.05 (b)"
      },
      "arbitration_clause": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "financing": {
    "committed_financing": {
      "committed_financing_present": {
        "answer": true,
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein.",
        "reference_section": "Section 4.07 (a)"
      },
      "committed_financing_summary": {
        "answer": "The committed financing arrangements include an equity financing commitment from the Investor, as outlined in the Equity Commitment Letter, which is a legal, valid, and binding obligation of Parent and the Investor.",
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein.",
        "reference_section": "Section 4.07 (a)"
      }
    },
    "financing_efforts_summary": {
      "financing_efforts_summary": {
        "answer": "Parent and Merger Sub have obligations to pursue financing as outlined in the Equity Commitment Letter and Debt Financing Cooperation clauses.",
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein... Prior to the Closing, the Company shall use commercially reasonable efforts to provide, and cause the Company Subsidiaries to provide, to Parent, at Parent's sole expense, such customary cooperation as is reasonably requested in writing by Parent in connection with the arrangement and consummation of any debt financing...",
        "reference_section": "Section 4.07"
      }
    },
    "substitute_financing_notice_and_efforts": {
      "substitute_financing_notice_and_efforts": {
        "answer": "Parent is required to use commercially reasonable efforts to keep the Company updated on any progress of the Debt Financing upon the reasonable request of the Company in writing.",
        "clause_text": "Prior to the Closing, Parent shall use commercially reasonable efforts to keep the Company updated on any progress of the Debt Financing, upon the reasonable request of the Company in writing.",
        "reference_section": "Section 6.11 (d)"
      }
    }
  },
  "proxy_statement": {
    "proxy_statement_filing_timing": {
      "proxy_statement_filing_timing": {
        "answer": "within sixty (60) days after the execution of this Agreement",
        "clause_text": "As promptly as practicable, but in any event within sixty (60) days after the execution of this Agreement and subject to (i) the receipt from Parent of any information required to complete the Proxy Statement that is requested by the Company and (ii) the exceptions set forth on Section 5.04 of the Company Disclosure Schedule, the Company shall, in consultation with Parent, prepare, and the Company shall file with the SEC, preliminary proxy materials which shall constitute the Proxy Statement...",
        "reference_section": "Section 5.04"
      }
    },
    "f4_effectiveness": {
      "f4_effectiveness_efforts": {
        "answer": "reasonable best efforts",
        "clause_text": "The Company shall use commercially reasonable efforts to file such Company SEC Document as promptly as reasonably practicable after the applicable deadline for the filing of such Company SEC Document.",
        "reference_section": "Section 6.14"
      },
      "f4_effectiveness_target_date": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "shareholder_meeting": {
      "shareholder_meeting_timing": {
        "answer": "within forty-five (45) days following the mailing of the Proxy Statement",
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the \"Company Stockholders' Meeting\")...",
        "reference_section": "Section 5.05"
      },
      "shareholder_meeting_deadline": {
        "answer": "45 days",
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the 'Company Stockholders' Meeting')...",
        "reference_section": "Section 5.05"
      },
      "shareholder_vote_efforts": {
        "answer": "The company is required to use reasonable best efforts to solicit proxies from its stockholders in favor of the approval of the adoption of the agreement.",
        "clause_text": "The Company shall... (ii) use reasonable best efforts to solicit from its stockholders proxies in favor of the approval of the adoption of this Agreement; provided that the Company shall not be required to so solicit if a Company Adverse Change Recommendation shall have been effected.",
        "reference_section": "Section 5.05"
      },
      "shareholder_meeting_postponment": {
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient Shares represented to constitute a quorum or to obtain the Required Company Stockholder Vote, with each adjournment, recess, or postponement not exceeding ten business days unless agreed otherwise. The Company may also adjourn, recess, or postpone the meeting to ensure any required supplement or amendment to the Proxy Statement is provided to stockholders, with Parent's written consent required for more than two occasions.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each) and (y) the Company may adjourn, recess, or postpone the Company Stockholders' Meeting to the extent necessary to ensure that any required supplement or amendment to the Proxy Statement is provided to the Company stockholders within a reasonable amount of time in advance of the Company Stockholders' Meeting; provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "Section 5.05"
      }
    },
    "parent_shareholder_meeting": {
      "parent_shareholder_meeting_timing": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "parent_shareholder_meeting_deadline": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "parent_shareholder_vote_efforts": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      },
      "parent_shareholder_meeting_postponment": {
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient Shares represented to constitute a quorum or to obtain the Required Company Stockholder Vote, with each adjournment, recess, or postponement not exceeding ten (10) business days unless agreed otherwise. The Company may also adjourn, recess, or postpone the meeting to ensure any required supplement or amendment to the Proxy Statement is provided to stockholders, with Parent's written consent required for more than two occasions.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each) and (y) the Company may adjourn, recess, or postpone the Company Stockholders' Meeting to the extent necessary to ensure that any required supplement or amendment to the Proxy Statement is provided to the Company stockholders within a reasonable amount of time in advance of the Company Stockholders' Meeting; provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "Section 5.05"
      }
    },
    "proxy_summary_notes": {
      "proxy_summary_notes": {
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient shares represented to constitute a quorum or obtain the Required Company Stockholder Vote.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each).",
        "reference_section": "Section 5.05"
      }
    },
    "dissenting_shares_cap": {
      "dissenting_shares_cap": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    }
  },
  "timeline": {
    "agreement_signing_date": {
      "agreement_signing_date": {
        "answer": "February 5, 2024",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    },
    "confidentiality_agreement_signing_date": {
      "confidentiality_agreement_signing_date": {
        "answer": "October 27, 2023",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the \"Confidentiality Agreement\").",
        "reference_section": "Section 5.01 (b)"
      }
    },
    "announcement_date": {
      "announcement_date": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "proxy_filing_deadline": {
      "proxy_filing_deadline": {
        "answer": "within sixty (60) days",
        "clause_text": "As promptly as practicable, but in any event within sixty (60) days after the execution of this Agreement and subject to (i) the receipt from Parent of any information required to complete the Proxy Statement that is requested by the Company and (ii) the exceptions set forth on Section 5.04 of the Company Disclosure Schedule, the Company shall, in consultation with Parent, prepare, and the Company shall file with the SEC, preliminary proxy materials which shall constitute the Proxy Statement...",
        "reference_section": "Section 5.04"
      }
    },
    "shareholder_vote_deadline": {
      "shareholder_vote_deadline": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "outside_date": {
      "outside_date": {
        "answer": "February 5, 2025",
        "clause_text": "by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the 'End Date');",
        "reference_section": "Section 8.01"
      },
      "outside_date_extension_list": {
        "answer": "1. Extension Length – 3 months; Who Grants the Extension – Automatic; Conditions to Extend – All conditions in Section 7.01, Section 7.02, and Section 7.03 must be satisfied or waived, except for certain specified conditions; Termination Restrictions Due to Breach – Yes, the party seeking termination must not have breached or failed to perform in a material respect causing the failure to consummate the Merger by the Test Date.",
        "clause_text": "This Agreement may be terminated...provided that such date shall automatically be extended by three (3) months on four (4) occasions...if, as of such date...all conditions set forth in Section 7.01, Section 7.02, and Section 7.03 shall have been satisfied or waived...the Party seeking to terminate this Agreement...shall not have breached or failed to perform in any material respect...",
        "reference_section": "Section 8.01"
      }
    },
    "hsr_filing_deadline": {
      "hsr_filing_deadline": {
        "answer": "20 business days after the date of this Agreement",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "Section 6.02 (c)"
      }
    },
    "second_request_deadline": {
      "second_request_deadline": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "cfius_filing_deadline": {
      "cfius_filing_deadline": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "marketing_period_dates": {
      "marketing_period_dates": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "inside_date": {
      "inside_date": {
        "answer": "Not found",
        "clause_text": "",
        "reference_section": ""
      }
    },
    "closing_date": {
      "closing_date": {
        "answer": "three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "Section 1.02"
      }
    },
    "conditions_satisfaction_end_date": {
      "conditions_satisfaction_end_date": {
        "answer": "February 5, 2025",
        "clause_text": "by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the \"End Date\"); provided that such date shall automatically be extended by three (3) months on four (4) occasions...",
        "reference_section": "Section 8.01"
      }
    }
  }
}